Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): 2014 update

Sheldon W Tobe1, James A Stone1, Kimberly M Walker1

  • 1Division of Nephrology (Tobe), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont.; Libin Cardiovascular Institute of Alberta (Stone), University of Calgary, Cardiac Wellness Institute of Calgary, Calgary, Alta.; University Health Network, Toronto General Hospital (Walker), Toronto, Ont.; Libin Cardiovascular Institute of Alberta (Anderson), University of Calgary Calgary Alta.; Women's College Hospital (Bhattacharrya), University of Toronto, Toronto, Ont.; Division of Endocrinology and Metabolism (Cheng), St. Michael's Hospital, University of Toronto, Toronto, Ont.; Institut de cardiologie de Montréal (Gregoire), Université de Montréal, Montréal, Que.; Division of Neurology (Gubitz), Dalhousie University, Halifax, NS.; Department of Nutritional Sciences (L'Abbé), University of Toronto, Toronto, Ont.; Division of Endocrinology and Metabolism (Lau), Julia McFarlane Diabetes Research Centre, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alta.; Keenan Research Centre (Leiter), Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ont.; Toronto Rehabilitation Institute (Oh), University Health Network, University of Toronto, Toronto, Ont.; Departments of Clinical Epidemiology and Pharmacology, and Division of General Internal Medicine (Padwal), University of Alberta, Edmonton, Alta.; Département de pharmacie, Centre Hospitalier Universitaire de Québec et Faculté de Pharmacie, Université Laval, Québec, Que.; Centre for Addiction and Mental Health, the Departments of Family and Community Medicine, and Psychiatry, and Dalla Lana School of Public Health (Selby), University of Toronto, Toronto, Ont.; The Children's Hospital of Eastern Ontario Research Institute (Tremblay), Ottawa, Ont.; the Department of Family Medicine (Ward), University of Calgary, Alta.; Sunnybrook Research Institute (Hua) Toronto, Ont.; University of Ottawa Heart Institute (Liu), Ottawa, Ont.

Abstract

No abstract available in PubMed .

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
742
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
884
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
440
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.1K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
789
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
997